Oxford University strikes licensing deal with Summit to develop drugs to combat Duchenne Muscular Dystrophy.

Oxford has signed a deal with pharmaceutical firm and spin-out Summit to further develop drugs which tackle Duchenne Muscular Dystrophy.

The muscle wasting disease affects one in every 3,500 boys, which leaves patients unable to walk by their teenage years and with a life expectancy of early thirties at the very most. Currently, there is no cure for the condition. However, Oxford scientists reckon that by targeting genes which control utrophine, which can help stabilise muscle membranes.

Dame Kay Davies,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?